OVERVIEW


Since its introduction in the early 1980s, magnetic resonance imaging (MRI) has become the most important laboratory diagnostic and monitoring tool for different chronic neurological disorders. MRI is five to ten times more sensitive than clinical data in the assessment of disease activity in multiple sclerosis. In the last decade, metrics derived from conventional MRI have been widely employed in therapeutic clinical trials in multiple sclerosis, Alzheimer’s disease, stroke, and epilepsy. A variety of conventional MRI protocols, in conjunction with clinical assessment, are now routinely used to detect therapeutic effects and extend clinical observations. In the past few years, measurement of global and regional brain atrophy has been introduced for the assessment of neurological disorders. Evaluation of brain atrophy appears to be a reliable surrogate marker in monitoring the destructive pathologic processes related to disease activity and clinical progression in multiple sclerosis, Alzheimer’s disease, stroke, and epilepsy. Therefore, in chronic neurological diseases with a high degree of longitudinal variability in clinical signs and symptoms within and between patients, and with no current adequate biological markers of disease progression, quantitative MRI techniques provide a powerful instrument to non-evasively evaluate different quantitative MRI markers at diagnosis and to monitor their change over time.

Currently, physicians in the United States and around the world use MRI in multiple sclerosis diagnosis and prognosis strictly with a qualitative approach. Nevertheless, there is an immediate need for quantitative MRI measures in clinical practice as useful tools for determining a diagnosis of MS as well as monitoring disease progression. In many chronic neurological diseases lasting more than 20-30 years, MRI-based monitoring may be important in optimizing therapeutic interventions. Furthermore, quantitative MRI techniques can also be used as surrogate outcome measures in clinical trials of new treatment therapies.

One of BNAC’s most important educational goals is to extend the knowledge about quantitative MRI techniques through informational and interactive web-based Continuing Medical Education (CME) programs for physicians, neurologists, radiologists, neuroradiologists, MS specialists, neurology residents, and MS nurse practitioners.

BNAC is partnering with Kenneth Alford Medical Education Center (KAMEC) to develop a number of such educational programs. The technical parts of the programs are developed using appropriate adult-learning instructional design techniques and state-of-the-art interactive media production elements. KAMEC combines medical content expertise with proven instructional design techniques to produce CME programs built on evidence-based medicine and reflecting broadcast-quality media production.

***Featuring our newest CME Interactive Web-Based Program:***

Other Previously Published CME Interactive Web-Based Program: